NewAmsterdam Pharma Company N.V. (NAMS) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
NAMS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 17, 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a price-to-earnings ratio of -20.3x, with a stock price of $35.44 and trailing twelve-month earnings per share of $-1.76.
Compared to the Healthcare sector median P/E of 21.4x, NAMS trades at a 194% discount to its sector peers. The sector includes 238 companies with P/E ratios ranging from 0.0x to 163.8x.
Relative to the broader market, NAMS trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NAMS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NAMS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 27.5 | - | -22% | |
| $144B | 18.6 | - | -4% | |
| $275B | 15.3Lowest | 0.72 | +8% | |
| $283B | 20.6 | 1.34 | +22% | |
| $282B | 27.8 | 1.27 | +191%Best | |
| $176B | 22.9 | 7.80 | +88% | |
| $73B | 16.8 | 2.66 | +8% | |
| $29B | 21.6 | 0.53Best | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See NAMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAMS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
Is NAMS stock overvalued or undervalued?
NAMS current P/E: -20.3x. 5-year average P/E: N/A. Percentile: N/A.
How does NAMS's valuation compare to peers?
NewAmsterdam Pharma Company N.V. P/E of -20.3x compares to sector median of 21.4x. The discount suggests lower growth expectations or higher risk.
What is NAMS's PEG ratio?
NAMS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.